| Date | Title | Description |
| 25.01.2022 | Not cheaper by the dozen: Bristol Myers becomes the 12th pharma company to restrict 340B sales | Bristol Myers Squibb recently joined 11 of its peer pharma companies in limiting how many contract pharmacies can access certain drugs discounted by a federal program known as 340B.
Bristol Myers is just the latest in ... |
| 04.03.2021 | CorVista Health Completes $65 Million Series C Equity Raise Bringing Total Funding to Nearly $100 Million | TORONTO--(BUSINESS WIRE)--Mar 4, 2021--
CorVista Health, Inc., a digital health company dedicated to improving cardiovascular disease diagnosis, today announced it has closed a $65 million Series C equity financing. This latest financing ro... |
| 03.03.2021 | Quantum Materials Corp Expands Executive Leadership Team To Execute Growth Strategy | SAN MARCOS, Texas--(BUSINESS WIRE)--Mar 3, 2021--
Quantum Materials Corp (QMC), today announced that it has recently appointed three members to executive leadership: Senior Vice President Clinical R&D and Regulatory Affairs Dr. John Car... |
| 02.03.2021 | Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference | WARREN, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious di... |
| 23.02.2021 | QMC HealthID Partners with Tried & Tested to Support COVID-19 Diagnostic Testing in the UK | SAN MARCOS, Texas--(BUSINESS WIRE)--Feb 23, 2021--
QMC HealthID, a wholly owned subsidiary of Quantum Materials Corp, today announced that it has partnered with Tried & Tested COVID-19 testing services. The QMC HealthID service will all... |
| 11.02.2021 | Panacea Acquisition : Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company | NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of it... |
| 11.02.2021 | NUVATION BIO INC.
Panacea Acquisition : Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company | NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of it... |
| 10.02.2021 | Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company | NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of it... |
| 05.01.2021 | IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors | Series A financing co-led by Nextech and Vida Ventures with participation from Two River Group, Bellco Capital, Polaris Partners, GV, Wellington Partners and Logos Capital
IconOVir formed by team behind Kite Pharma, Allogene Therapeutics an... |
| 06.10.2020 | Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors | Four Additional Board Members Appointed to Complement Founding Expertise
NEW YORK & AMSTERDAM–(BUSINESS WIRE)–October 6, 2020–
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully person... |
| 14.09.2020 | Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies | Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River
Neogene’s proprietary technology platform identifies specific T cell receptor (TCR) genes... |
| 17.01.2018 | Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer | AUSTIN, Texas– Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, today announced that it has exp... |
| 20.02.2017 | 8 Ways to Leverage TV Appearances to Build Your Brand | Getting on TV is the startup founder's dream. Whether it's a local news segment or a popular pitch competition show, having a natural marketing opportunity like TV is a great way to facilitate success. But don’t let an appearance on “Shark ... |
| 07.09.2016 | Mountaingate Capital-backed W2O Group Acquires Pure Communications | SAN FRANCISCO & WILMINGTON, N.C.–(BUSINESS WIRE)–W2O Group, a network of complementary, digitally oriented, analytics-directed communications and marketing firms, today announced the acquisition of Pure Communications, LLC, a leading st... |
| 10.03.2016 | The All You Can Eat 24-Hour Buffet: SXSW Interactive Kicks off | BY LAURA LOREK
Reporter with Silicon Hills News |
| 10.03.2016 | Robert Scoble Leaves Rackspace for UploadVR | Robert Scoble, who has worked in various roles with Rackspace for the past seven years, announced Thursday he is leaving the San Antonio-based tech company to join UploadVR. |
| 06.09.2015 | W2O Group Acquires Fox Communications | W2O Group, an independent network of complementary marketing, communications, research and development firms, acquired Fox Communications, a communications firm based in San Francisco.
The amount of the deal was not disclosed.
Following the... |
| 18.12.2014 | Juno Therapeutics Announces Pricing of Initial Public Offering | December 18, 2014 06:14 PM Eastern Standard Time |
| 20.03.2014 | The Austin Chamber Releases Hot Trends and Topics from SXSW | Now that the madness of South by Southwest Interactive has subsided, it’s time to reflect on all the lessons learned from one of the world’s largest technology conferences. |
| 19.04.2012 | W20 Group acquires Austin-based Ravel | W2O Group has acquired Austin-based Ravel.
All of Ravel’s employees will join W2O Group. The company also has acquired all of Ravel’s big data technology, pending patents and software assets.
The terms of the deal were not disclosed.
CEO Ji... |
| - | Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 2, 2021--
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call today outlining the Company’s ... |
| - | Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 3, 2021--
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported fi... |
| - | SQZ Biotechnologies Reports 2020 Financial Results and Recent Advancements | WATERTOWN, Mass.--(BUSINESS WIRE)--Mar 18, 2021--
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and recent business highli... |
| - | Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years | BRISBANE, Calif.--(BUSINESS WIRE)--Feb 25, 2021--
Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pool... |
| - | QMC HealthID Partners with PopupRx; Deploys HealthID Solution Within Pharmacies Across Texas | SAN MARCOS, Texas--(BUSINESS WIRE)--Mar 17, 2021--
QMC HealthID, a wholly owned subsidiary of Quantum Materials Corp and supplier of management platforms and mobile apps that authenticate the process of infectious disease testing and report... |
| - | CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies | Cologne, Germany and Philadelphia, PA, USA February 2, 2021 - CEVEC Pharmaceuticals GmbH (CEVEC) and CARISMA Therapeutics Inc. (CARISMA) today announced the signing of an agreement which grants CARISMA a clinical and commercial license for ... |
| - | CARISMA Therapeutics Completes Series B Financing Totaling $59 Million | PHILADELPHIA, March 1, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringi... |
| - | Balancing tensions amid a global health crisis: The quest for relevance | According to Johns Hopkins University & Medicine, as of mid-May, confirmed cases of Covid-19 have reached nearly 5 million worldwide and almost 320,000 people have died. Even though these numbers continue to climb, it appears that in ma... |
| - | Five things to know about the rapid acceleration of digital health | SXSW conversation reveals doctors and patients predict more transformation ahead
Last month, Real Chemistry — a global health innovation company — brought together leading innovators at SXSW to discuss the issues driving the health care ind... |
| - | Epizyme to Host Strategic Vision Call on March 2, 2021 | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2021--
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that it will host a call to disc... |
| - | SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs at the American Association for Cancer Research (AACR) 2021 Annual Meeting | WATERTOWN, Mass.--(BUSINESS WIRE)--Mar 10, 2021--
SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present data on the next genera... |
| - | SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference | WATERTOWN, Mass.--(BUSINESS WIRE)--Mar 3, 2021--
SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ™, wil... |
| - | Real Chemistry and the Media Empathy Foundation Partner at SXSW, Launching “Culture Care” to Reduce Disease-Related Stigma and Bias Through Data-Driven Creative Content | SAN FRANCISCO--(BUSINESS WIRE)--Mar 18, 2021--
Global health innovation company Real Chemistry announced today at the 2021 SXSW Healthcare Media Lounge that it is partnering with the non-profit Media Empathy Foundation to deliver “Culture C... |
| - | Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 9, 2021--
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced t... |
